In This Article:
Looking at AN2 Therapeutics, Inc.'s (NASDAQ:ANTX ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold.
While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
View our latest analysis for AN2 Therapeutics
AN2 Therapeutics Insider Transactions Over The Last Year
Over the last year, we can see that the biggest insider purchase was by Co-founder Eric Easom for US$54k worth of shares, at about US$5.38 per share. Even though the purchase was made at a significantly lower price than the recent price (US$14.31), we still think insider buying is a positive. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.
You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).
Insider Ownership
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. AN2 Therapeutics insiders own about US$27m worth of shares. That equates to 6.3% of the company. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.
So What Do The AN2 Therapeutics Insider Transactions Indicate?
It doesn't really mean much that no insider has traded AN2 Therapeutics shares in the last quarter. On a brighter note, the transactions over the last year are encouraging. Insiders own shares in AN2 Therapeutics and we see no evidence to suggest they are worried about the future. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. At Simply Wall St, we've found that AN2 Therapeutics has 4 warning signs (2 make us uncomfortable!) that deserve your attention before going any further with your analysis.
But note: AN2 Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.